"Busulfan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
| Descriptor ID |
D002066
|
| MeSH Number(s) |
D02.033.455.125.125 D02.455.326.146.100.050.500.100 D02.886.645.600.055.050.510.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Busulfan".
Below are MeSH descriptors whose meaning is more specific than "Busulfan".
This graph shows the total number of publications written about "Busulfan" by people in this website by year, and whether "Busulfan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 1 | 4 |
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 1 | 2 |
| 1997 | 2 | 0 | 2 |
| 1999 | 1 | 2 | 3 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 5 | 1 | 6 |
| 2003 | 2 | 2 | 4 |
| 2004 | 3 | 1 | 4 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 1 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 1 | 3 | 4 |
| 2010 | 3 | 4 | 7 |
| 2011 | 1 | 3 | 4 |
| 2012 | 2 | 4 | 6 |
| 2013 | 1 | 3 | 4 |
| 2014 | 3 | 4 | 7 |
| 2015 | 5 | 4 | 9 |
| 2016 | 6 | 2 | 8 |
| 2017 | 3 | 5 | 8 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 4 | 5 |
| 2020 | 4 | 9 | 13 |
| 2021 | 3 | 4 | 7 |
| 2022 | 0 | 6 | 6 |
| 2023 | 1 | 5 | 6 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Busulfan" by people in Profiles.
-
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity. Blood Adv. 2024 10 08; 8(19):5137-5145.
-
Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2024 Aug; 103(8):3083-3093.
-
ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. Oncotarget. 2024 Mar 14; 15:220-231.
-
Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts. Am J Hematol. 2024 02; 99(2):245-253.
-
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv. 2023 10 24; 7(20):6196-6205.
-
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther. 2023 Dec; 29(12):770.e1-770.e6.
-
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 07 01; 108(7):1900-1908.
-
Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
-
Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy. Bone Marrow Transplant. 2023 06; 58(6):635-638.
-
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. Eur J Haematol. 2023 Mar; 110(3):305-312.